BioCentury | Oct 3, 2016
Strategy

Combo deals

...CD195 ) and CCR2 ( CD192 ) antagonist that is in Phase IIb testing, and evogliptin...
...all patients. He said cenicriviroc's mechanism addresses inflammatory and fibrosis drivers, while Tobira's DPP-4 inhibitor evogliptin...
BioCentury | Sep 26, 2016
Clinical News

Cenicriviroc: Phase I started

...Tobira began an open-label, U.S. Phase I trial to evaluate 5 mg oral evogliptin with or...
...a single agent or in combination with evogliptin while Dong-A granted Tobira exclusive rights to evogliptin...
...in combination with cenicriviroc in the U.S., Canada, Europe and Australia (see BioCentury, April 26). Evogliptin...
BioCentury | Sep 26, 2016
Clinical News

Evogliptin: Phase I started

...Tobira began an open-label, U.S. Phase I trial to evaluate 5 mg oral evogliptin with or...
...a single agent or in combination with evogliptin while Dong-A granted Tobira exclusive rights to evogliptin...
...Ltd. (KSE:170900), Seoul, South Korea Tobira Therapeutics Inc. (NASDAQ:TBRA), San Francisco, Calif. Product: Evogliptin ( DA-1229...
BioCentury | Sep 26, 2016
Company News

Tobira, Allergan deal

...endpoint in the Phase IIb CENTAUR trial to treat NASH. Allergan also gains evogliptin ( DA-1229...
...will continue to explore combination therapies with the two products. Tobira has exclusive rights to evogliptin...
...and Australia from Dong-A ST Co. Ltd. (KSE:170900, Seoul, South Korea). Evogliptin is approved as Suganon...
BioCentury | Sep 20, 2016
Top Story

Allergan acquiring NASH companies Tobira, Akarna

...from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502). The deal also gives Allergan gastroenterology candidate evogliptin ( DA-1229...
...inhibitor is in development in combination with cenicriviroc for NASH. Tobira has rights to evogliptin...
BioCentury | Apr 25, 2016
Company News

Tobira, Dong-A ST deal

...rights to develop and commercialize cenicriviroc as a single agent and in combination with Dong-A’s evogliptin...
...milestones, plus tiered royalties. Evogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is approved in Korea as Suganon...
BioCentury | Apr 25, 2016
Company News

Dong-A ST, Tobira deal

...Dong-A granted Tobira exclusive rights to develop and commercialize evogliptin as a single agent or in...
...indication later this year. Evogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is approved in Korea as Suganon...
Items per page:
1 - 7 of 7